Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.42 |
| ▸ | CCNC | P24863 | 2/20 | 0.35 |
| ▸ | CDK8 | P49336 | 2/20 | 0.35 |
| ▸ | MAP3K12 | Q12852 | 5/20 | 0.34 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.32 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.31 |
| ▸ | MAP4K1 | Q92918 | 4/20 | 0.30 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.30 |
| ▸ | MTOR | P42345 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL248167 | 0.81 | PIK3CA (0.46) | PDE10AACVR1LRRK2MAP4K1PIK3CA | |
| SCHEMBL249136 | 0.79 | PDE10A (0.40) | PDE10ACCNCCDK8MAP3K12 | |
| SCHEMBL248398 | 0.72 | DHFR (0.37) | PDE10AACVR1 | |
| SCHEMBL248192 | 0.69 | LRRK2 (0.39) | MAP3K12ACVR1LRRK2MAP4K1PIK3CA | |
| SCHEMBL14849212 | 0.68 | PDE10A (0.39) | PDE10A | |
| SCHEMBL31508129 | 0.66 | PDE10A (0.41) | PDE10ACCNCCDK8MAP3K12LRRK2 | |
| SCHEMBL25925600 | 0.66 | BRD9 (0.42) | PDE10ACCNCCDK8MAP3K12ACVR1 | |
| SCHEMBL248529 | 0.65 | GCK (0.40) | PDE10APIK3CAMTOR | |
| SCHEMBL10187281 | 0.65 | LRRK2 (0.42) | PDE10AMAP3K12LRRK2 | |
| SCHEMBL2791709 | 0.65 | PDE10A (0.46) | PDE10ACCNCCDK8MAP3K12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2588471-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PI3K ACTIVITY | Amgen Inc. (US) | 2013-05-08 | — | — | EP | disclosed |
| US-20130090323-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2013-04-11 | — | — | US | disclosed |
| WO-2012003283-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PI3K ACTIVITY | AMGEN INC. (US) | 2012-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130090323-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, MALT1, BCL9 | PDE10A 3392/4885CCNC 239/4885CDK8 44/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.